Skip to main content
TipRanks
Go Ultimate75% OFF

CAMP4 Therapeutics Corporation (CAMP) AI Stock Analysis

146 Followers
CAMP

CAMP4 Therapeutics Corporation

(NASDAQ:CAMP)

Select Model
Rating:47Neutral
Price Target:$3.50â–¼(-14.63% Downside)
Action:reiterated
Date:11/06/26

The score is primarily held down by weak financial performance (large losses and continued cash burn on a small, declining revenue base), partially offset by a comparatively healthier balance sheet with low leverage. Technicals are mixed with neutral momentum but a weaker longer-term trend, and valuation provides limited support due to a negative P/E and no dividend yield data.

Positive Factors
Clinical executionObtaining clearances across several jurisdictions and launching ASCEND represent meaningful clinical execution for a small biotechnology company. The global trial infrastructure can support development of CMP-002 in SYNGAP1-related disorder and advance the lead program toward future efficacy evidence.
Negative Factors
Large operating lossesThe company’s current revenue base is very small relative to its losses, with profitability roughly negative 35 times revenue. This substantial mismatch shows that operating costs remain far ahead of commercial scale, limiting evidence that the business can generate sustainable earnings in the near term.

CAMP4 Therapeutics Corporation (CAMP) vs. SPDR S&P 500 ETF (SPY)

-25%0%25%50%75%100%125%150%CAMP+41.38%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$257.29M
Dividend Yield
―
Average Volume (3M)
242.41K
Price to Earnings (P/E)
-2.0
Beta (1Y)
1.78
Revenue Growth
39.93%
EPS Growth
16.95%
Country
US
Employees
48
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

CAMP4 Therapeutics Corporation Business Overview & Revenue Model

Company Description

CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.

CAMP4 Therapeutics Corporation Earnings Call Summary

Earnings Call Date:Nov 21, 2024(Q3-2024)|% Change Since:-29.07%|Next Earnings Date:Apr 01, 2027
Earnings Call SentimentNeutral

The earnings call presented a mixed picture with strong strategic initiatives, cost reduction measures, and new product launches countered by significant revenue and gross margin declines, as well as a notable goodwill impairment.

Positive Updates

Successful Migration to New Device Management System
CalAmp completed the migration of over 8.5 million devices from the legacy PULS system to the new DMCTC, enhancing functionality and benefits for TSP customers.

Negative Updates

Revenue Decline
Total revenues for Q3 FY '24 were $53.6 million, down 32% year-over-year and 13% sequentially, primarily due to reduced sales to TSP customers.

Company Guidance

During the CalAmp Corp. Q3 FY '24 Earnings Call, several key metrics and guidance were discussed. The company reported total revenues of $53.6 million, marking a 32% year-over-year and 13% sequential decline, primarily due to reduced sales to TSP customers. Adjusted EBITDA was $1 million, or 2% of revenues, which was below expectations due to lower revenue and gross margin. Recurring application subscription revenue was $17.8 million, with declines in the connected car U.K. operations offset by growth in the K-12 segment. Gross margin decreased to 33% from the previous quarter’s 36%. The call highlighted a cost-reduction initiative expected to save approximately $16 million annually, reducing the adjusted EBITDA breakeven point to $42 million in quarterly revenue. The strategic financing agreement with Lynrock Lake, involving a $45 million term loan, aims to enhance liquidity and support restructuring efforts. Looking ahead, the company anticipates a slight decrease in consolidated revenues with stable adjusted EBITDA in Q4, expecting industrial market segment revenues to normalize while seeing some recovery in TSP customer orders.

CAMP4 Therapeutics Corporation Financial Statement Overview

Summary

Overall financial profile is weak due to very small and declining TTM revenue ($3.4M, -18.9% growth), very large losses (net loss $121.1M), and ongoing cash burn (TTM operating cash flow -$25.5M; free cash flow -$26.4M). The main offset is a relatively stronger balance sheet with low leverage (debt-to-equity ~0.06) and improved equity versus 2023, but profitability and cash flow remain the dominant constraints.

Income Statement

22Negative

Balance Sheet

58Neutral

Cash Flow

27Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Nov 2023Feb 2023Feb 2022
Income Statement
Total Revenue5.32M3.50M652.00K350.00K294.95M295.84M
Gross Profit4.28M1.86M652.00K350.00K109.01M121.89M
EBITDA-86.40M-50.42M-51.39M-50.20M-24.20M-2.64M
Net Income-121.10M-80.40M-51.79M-49.29M-32.49M-27.99M
Balance Sheet
Total Assets134.01M117.81M78.31M54.95M102.55M402.29M
Cash, Cash Equivalents and Short-Term Investments124.52M109.52M64.04M38.38M83.19M91.11M
Total Debt6.45M1.97M8.65M11.69M12.39M209.17M
Total Liabilities26.92M70.10M15.16M178.68M180.08M322.11M
Stockholders Equity107.09M47.70M63.14M-123.73M-77.53M80.18M
Cash Flow
Free Cash Flow-26.41M-29.83M-46.00M-44.83M-42.57M-17.52M
Operating Cash Flow-25.54M-29.55M-45.56M-44.16M-38.54M-4.22M
Investing Cash Flow-869.00K-243.00K-441.00K-678.00K-4.03M-7.58M
Financing Cash Flow75.67M75.89M71.66M301.00K100.16M-2.64M

CAMP4 Therapeutics Corporation Technical Analysis

Technical Analysis SentimentPositive
Last Price4.10

Price Trends

50DMA3.84Positive
100DMA3.98Positive
200DMA4.20Negative

Market Momentum

MACD0.09Negative
RSI54.91Neutral
STOCH30.65Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CAMP, the sentiment is Positive. The current price of 4.10 is above the 20-day moving average (MA) of 3.86, above the 50-day MA of 3.84, and below the 200-day MA of 4.20, indicating a neutral trend. The MACD of 0.09 indicates Negative momentum. The RSI at 54.91 is Neutral, neither overbought nor oversold. The STOCH value of 30.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CAMP.

CAMP4 Therapeutics Corporation Risk Analysis

CAMP4 Therapeutics Corporation disclosed 87 risk factors in its most recent earnings report. CAMP4 Therapeutics Corporation reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk
1.We have received orphan drug designation for CMP-001 and CMP-002 in certain jurisdictions, are pursuing orphan drug designation for CMP-002 in the United States, and may seek orphan drug designation for other product candidates in the future. We may not be able to obtain or maintain the benefits of orphan drug designation, including potential orphan drug exclusivity, and even if we do, that exclusivity may not prevent regulatory authorities from approving other competing products.Q1, 2026

CAMP4 Therapeutics Corporation Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CAMP against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
RLMDRLMD48Neutral$304.61M-3.86-37.25%――58.31%
CAMPCAMP47Neutral$251.02M-2.00-261.83%―39.93%16.95%
BYSIBYSI45Neutral$18.76M0.41-208.57%―――
INKTINKT45Neutral$47.67M-3.95107.71%――25.94%
OSTXOSTX43Neutral$38.95M-0.831.47%――-30.21%
ARTVARTV40Underperform$190.81M-1.26-45.32%――7.78%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%CAMPRLMDBYSIINKTARTVOSTXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CAMP and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CAMPCAMP4 Therapeutics Corporation4.100.5916.81%
RLMDRelmada Therapeutics Inc2.85-1.47-33.91%
BYSIBeyondspring0.45-1.29-73.97%
INKTMink Therapeutics, Inc.8.84-2.04-18.75%
ARTVArtiva Biotherapeutics, Inc.3.770.6018.93%
OSTXOS Therapies Incorporated0.92-0.70-43.27%

CAMP4 Therapeutics Corporation Corporate Events

Business Operations and Strategy

CAMP4 Details ASCEND Trial Plans in SYNGAP1 Disorder

Positive
Sep 28, 2026

On September 28, 2026, CAMP4 Therapeutics held an Analyst Day to detail the design of its planned Phase 1/2 ASCEND trial of CMP-002 in SYNGAP1-related disorder, a randomized, double-blind, placebo-controlled multiple ascending dose study in children...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026